| Literature DB >> 35743631 |
Minoo Sharbafshaaer1,2, Francesca Trojsi2, Simona Bonavita2, Amirreza Azimi1.
Abstract
Cognitive impairment (CI) occurs in about 40-65% of people with multiple sclerosis (MS) during the disease course. Cognitive rehabilitation has produced non-univocal results in MS patients.Entities:
Keywords: cognitive functions; integrated cognitive rehabilitation; multiple sclerosis
Year: 2022 PMID: 35743631 PMCID: PMC9224682 DOI: 10.3390/jcm11123560
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Flowchart of intervention.
Figure 2The Integrative Cognitive Rehabilitation Program Theoretical Model.
Demographic and clinical characteristics of the experimental and control groups.
| Characteristic | Experimental Group (n = 20) | Control Group (n = 20) |
|
|
| |
|---|---|---|---|---|---|---|
|
| Mean (SD) | 1.3 ± 0.47 | 1.2 ± 0.41 | 149.00 | 39 | 0.988 |
| Female (%) | 14 (70) | 16 (80) | ||||
| Male (%) | 6 (30) | 4 (20) | ||||
|
| Mean (SD) | 34.15 ± 8.36 | 31.85 ± 8.25 | 0.512 | 1 | 0.774 |
| 18–30 (%) | 7 (35) | 10 (50) | ||||
| 31–43 (%) | 9 (45) | 7 (35) | ||||
| 44–56 (%) | 4 (20) | 3 (15) | ||||
|
| Mean (SD) | 7.6 ± 4.32 | 7.8 ± 2.28 | 4.489 | 1 | 0.106 |
| 2–8 (%) | 15 (75) | 14 (70) | ||||
| 9–14 (%) | 3 (15) | 3 (15) | ||||
| 15–21 (%) | 2 (10) | 3 (15) | ||||
|
| Mean (SD) | 1.3 ± 0.47 | 1.2 ± 0.41 | 208.00 | 39 | 0.072 |
| With history (%) | 6 (30) | 4 (20) | ||||
| Without history (%) | 14 (70) | 16 (80) | ||||
|
| Mean (SD) | 1.75 ± 0.85 | 1.5 ± 0.82 | 4.305 | 1 | 0.116 |
| Relapsing-remitting (RRMS) (%) | 10 (50) | 14 (70) | ||||
| Primary-progressive MS (PPMS) (%) | 5 (25) | 2 (10) | ||||
| Secondary-progressive (SPMS) (%) | 5 (25) | 4 (20) | ||||
|
| Interferon β-1b (%) | 4 (20) | 5 (25) | 190.00 | 39 | 0.892 |
| Glatiramer acetate (%) | 6 (30) | 5 (25) | ||||
| Ocrelizumab (%) | 10 (50) | 10 (50) | ||||
Notes: SD; standard deviation; CI: confidence interval; df: degrees of freedom; N = total number of samples; U: Mann–Whitney U test; x2; Kruskal–Wallis.
Performance on neuropsychological measures for the ICRP group and control group at baseline, posttreatment, and at 3-month follow-up.
| Measure | Time Period | Experimental Group | Control Group | ||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||
|
| T0 | 3/37 | 0/413 | 3/10 | 0/391 |
| T1 | 3/68 | 0/418 | 3/33 | 0/395 | |
| T2 | 6/75 | 0/827 | 3/75 | 0/401 | |
|
| T0 | 2/80 | 0/89 | 2/40 | 0/50 |
| T1 | 4 | 0/77 | 2/80 | 0/41 | |
| T2 | 5/20 | 0/76 | 3/20 | 0/41 | |
|
| T0 | 0/42 | 0/22 | 0/49 | 0/27 |
| T1 | 0/62 | 0/15 | 0/50 | 0/27 | |
| T2 | 0/88 | 0/08 | 0/52 | 0/28 | |
|
| T0 | 0/81 | 0/09 | 0/76 | 0/03 |
| T1 | 0/84 | 0/07 | 0/78 | 0/03 | |
| T2 | 0/90 | 0/007 | 0/78 | 0/02 | |
Notes: All values are raw scores. T: Time, T0: baseline assessment; T1: posttreatment assessment; T2: 3-month follow-up assessment. CVLT: California Verbal Learning Test, BVMTR: Brief Visuospatial Memory Test.
Two-way mixed-effect ANOVA for cognitive domain performance: time (within subjects’ factor) and patient group: (between subjects’ factor).
| Value |
| Effect Size | Observed Power | |||
|---|---|---|---|---|---|---|
|
| Time | 0.363 | 66.681 | 0.000 | 0.637 | 1 |
| Time × group | 0.494 | 38.816 | 0.000 | 0.505 | 1 | |
|
| Time | 0.089 | 389.120 | 0.000 | 0.911 | 1 |
| Time × group | 0.281 | 97.280 | 0.000 | 0.719 | 1 | |
|
| Time | 0.276 | 48.623 | 0.000 | 0.724 | 1 |
| Time × group | 0.339 | 36.124 | 0.000 | 0.661 | 1 | |
|
| Time | 0.328 | 37.913 | 0.000 | 0.672 | 1 |
| Time × group | 0.697 | 8.005 | 0.001 | 0.302 | 0.95 |
Notes: F: ANOVA Wilks’ Lambda (interaction effect), Effect size; (r) 0.1 small size; 0.3 medium size; 0.5 large size. Observed power (or post hoc power) is the statistical power of the test performed. CVLT: California Verbal Learning Test, BVMTR: Brief Visuospatial Memory Test.
Figure 3Composite auditory/verbal learning (CVLT)performance (z-scores) in the ICRP intervention group and control group at baseline and posttreatment.
Figure 4Composite visual/spatial memory (BVMTR) performance (z-scores) in the ICRP intervention group and control group at baseline and posttreatment.
Figure 5Composite attention performance (z-scores) in the ICRP intervention group and control group at baseline and posttreatment.
Figure 6Composite executive function performance (z-scores) in the ICRP intervention group and control group at baseline and posttreatment.
Comparison of neuropsychological test scores for the standard care MS control group at baseline and posttreatment.
| Baseline | Posttreatment | 3-Month Follow-Up | Baseline versus Posttreatment | Effect Size (r) | Baseline versus Follow-Up | ||||
|---|---|---|---|---|---|---|---|---|---|
| Mean | Median | Mean | Median | Mean | Median | ||||
|
| 38.55 | 38 | 44.50 | 43.50 | 50.45 | 48.50 | 0.000 *** | 0.996 | 0.000 |
|
| 2.80 | 2.50 | 4 | 3.75 | 5.20 | 5 | 0.000 *** | 0.996 | 0.000 |
|
| 0.427 | 0.445 | 0.626 | 0.670 | 0.887 | 0.90 | 0.000 *** | 0.944 | 0.000 |
|
| 0.811 | 0.840 | 0.847 | 0.875 | 0.909 | 0.910 | 0.000 *** | 0.997 | 0.000 |
Notes: All values are raw scores (*** p < 0.001). Friedman’s nonparametric test was used for the comparison of medians between baseline, posttreatment, and follow-up. Wilcoxon test with Holm–Bonferroni correction used for pairwise comparisons. CVLT: California Verbal Learning Test, BVMTR: Brief Visuospatial Memory Test.